Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Diagnosing Heart Failure – Experience and ‘Best Pathways’
Author(s): Clare Taylor , Richard Hobbs Added: 3 years ago
Heart failure is a complex clinical syndrome that results from a structural or functional cardiac abnormality. The prevalence of heart failure is likely to increase as the population ages and survival rates following myocardial infarction continue to improve.1 Morbidity and mortality rates are significant and relate to high healthcare costs in terms of hospital admissions and long-term care.2… View more

Imaging & Diagnostics

Heart Failure
Testosterone and the Heart
Author(s): Michael G Kirby , Geoffrey Hackett , Sudarshan Ramachandran Added: 3 years ago
Testosterone deficiency (TD) is a well-established and significant medical condition.1,2 It has been defined as a clinical and biochemical syndrome, associated with older age and comorbidities.3 It is characterised by a deficiency in serum androgen levels, with or without reduced genomic sensitivity to androgens.2 The latter relates to the functionality of androgen receptors. For example, if… View more

Heart Failure

Electrophysiology & Arrhythmia
HFA 23: DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF
Author(s): Domingo Figal Added: 11 months ago
ESC-HFA 2023 — Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352). The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from ESC Heart Failure 2023 revealed that dapagliflozin… View more

Heart Failure
ACC 22: Results from the GIPS-IV Trial
Author(s): Pim van der Harst , Added: 2 years ago
In this short interview from our coverage of the ACC.22 late-breaking trials, Dr Pim van der Harst and Dr Marie-Sophie de Koning (University Medical Center Groningen, NL) discuss the data from the GIPS-IV trial which investigates the safety and efficacy of the hydrogen sulfide (H2S) donor sodium thiosulfate (STS) in patients presenting with ST-segment elevation myocardial infarction (STEMI) … View more

MI/ACS
Left Ventricular Remodelling: A Problem in Search of Solutions
Author(s): Dennis V Cokkinos , Christos Belogianneas Added: 3 years ago
The term cardiac remodelling (REM) is used to define changes that produce geometrical rearrangement of the normal structures of the heart, together with complex biological and molecular alterations. REM affects the heart at the level of the cardiomyocyte, the blood vessels and the extracellular matrix. Proliferation of the latter, resulting in fibrosis, is one of the hallmarks of pathological REM… View more

Heart Failure
SECURE, ADVOR and REVIVED: Clinical Trials Presented at ESC 2022
Author(s): Guiomar Mendieta Added: 1 year ago

Vascular Disease and Surgery

Heart Failure
HF 22: 6M Results of a No-Implant Interatrial Shunt in Pts With Chronic HF
Author(s): Lars H Lund Added: 1 year ago
Prof Lars Lund (Karolinska Institute, SE) outlines the findings of the ALLEVIATE-HF-1 and ALLEVIATE-HF-2 studies at 6 months. Presented at Heart Failure 22, this study aimed to evaluate a no-implant shunt in patients with chronic heart failure. Discussion Points: 1. Aims of This Study 2. No-Implant Interatrial Shunt 3. Inclusion and Exclusion Criteria, Patient Cohort and Study Design 4. Key… View more

Heart Failure
Author(s): Holger Woehrle , Jochen Müller-Ehmsen , Erland Erdmann Added: 3 years ago
Abstract Sleep-disordered breathing (SDB) is a common finding in patients with cardiovascular disease (CVD). SDB can cause negative effects on the cardiovascular system and can contribute to the worsening of the underlying disease. Obstructive sleep apnoea (OSA) is a major independent risk factor for the manifestation and progression of cardiovascular diseases, whereas central sleep apnoea (CSA)… View more

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
Author(s): Merce Faraudo , Paola Beltran , Román Freixa Pamias , et al Added: 3 years ago
Topic: 3. Heart Failure and Cardiomyopathy Introduction and Objectives LCZ696 has been considered class I B in the recent ESC Guidelines of heart failure (HF) for stable HF patients with left ventricular ejection fraction (LVEF) < 35%, who remain symptomatic after the standard therapy, based on the results of the PARADIGM trial. This study showed a significant reduction in the risk of… View more

Heart Failure
SGLT-2 Inhibitors and Cardio-renal Outcomes
Author(s): Shelley Zieroth , , Added: 2 years ago
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Dr Shelley Zieroth (University of Manitoba, CA), Prof Hiddo L Heerspink (University Medical Center, Groningen, NL) andProf Kamlesh Khunti (University of Leicester, UK) discuss the implications for practice. This three-part series, 'SGLT-2 Inhibitors and Cardio-renal… View more

Heart Failure

Prevention & Chronic Conditions